SAB Biotherapeutics (SABS) Prepaid Assets (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Prepaid Assets data on file, last reported at $3.8 million in Q1 2026.

• Quarterly Prepaid Assets rose 11.98% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 11.98% YoY) and the FY2025 annual result came in at $3.5 million, up 18.03% from the prior year.
• Prepaid Assets improved to $3.8 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Prepaid Assets ranged from a high of $3.8 million in Q1 2026 to a low of $702231.0 in Q3 2023.
• A 5-year average of $2.2 million and a median of $2.0 million in 2024 frame the typical range for Prepaid Assets.
• Annual changes were most pronounced in 2022 — Prepaid Assets jumped 1038.56% — and 2023, when it slumped 59.57%.
• Tracing SABS's Prepaid Assets over 5 years: stood at $1.5 million in 2022, then surged by 56.68% to $2.3 million in 2023, then advanced by 27.16% to $3.0 million in 2024, then increased by 18.03% to $3.5 million in 2025, then gained by 9.17% to $3.8 million in 2026.
• The last three Prepaid Assets figures came in at $3.8 million (Q1 2026), $3.5 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.